Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-25
SponsorCentre Hospitalier Universitaire de la Guadeloupe

About this trial

Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or shock syndrome. Several recent reports have shown that sickle cell patients exhibited an increased risk of developing severe forms of dengue episodes compared to non-sickle cell subjects. Furthermore, among major sickle cell syndromes, these studies suggest that SC patients are at the highest risk of death during these infectious episodes although this sickle cell syndrome is generally associated with a more moderate expression of sickle cell disease. However, the mechanisms involved remain unknown to date.

The aim of the present study is to identify the molecular and cellular basis of this increased severity of dengue in SC patients. We hypothesize an exacerbation during DENV infection of the inflammatory response in SC patients compared to SS patients.

Eligibility criteria

Qualifiers

patients with SS or SC SCD or controls with hemoglobin AA

diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies

patients older than 6 years and younger than 25 at inclusion

clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)

Disqualifiers

patients with SS or SC SCD or controls with hemoglobin AA

diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies

patients older than 6 years and younger than 25 at inclusion

clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

130 Participants
are grouped into 3 trial groups